Indoramin: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
 
Line 1: Line 1:
__NOTOC__
{{Drugbox
{{drugbox |
| Verifiedfields = changed
| IUPAC_name = ''N''-[1-[''2''-(1H-indol-3-yl)ethyl]-4-piperidyl]benzamide
| verifiedrevid = 461936008
| IUPAC_name = ''N''-{1-[2-(1''H''-indol-3-yl)ethyl]piperidin-4-yl}benzamide
| image = Indoramin_svg.png
| image = Indoramin_svg.png
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|indoramin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL        / P      / POM / CD -->
| legal_US = <!-- OTC                  / Rx-only  -->
| legal_status = 
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 26844-12-2
| CAS_number = 26844-12-2
| ATC_prefix = C02
| ATC_prefix = C02
| ATC_suffix = CA02
| ATC_suffix = CA02
| PubChem = 33625
| PubChem = 33625
| DrugBank =  
| IUPHAR_ligand = 501
| C=22 | H=25 | N=3 | O=1
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 31014
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0Z802HMY7H
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04531
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 279516
 
<!--Chemical data-->
| C=22 | H=25 | N=3 | O=1  
| molecular_weight = 347.454 g/mol
| molecular_weight = 347.454 g/mol
| bioavailability =  
| smiles = O=C(c1ccccc1)NC4CCN(CCc3c2ccccc2nc3)CC4
| protein_bound =  
| InChI = 1/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
| metabolism =  
| InChIKey = JXZZEXZZKAWDSP-UHFFFAOYAC
| elimination_half-life =  
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| excretion =
| StdInChI = 1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| pregnancy_US =  <!-- A / B            / C / D / X -->
| StdInChIKey = JXZZEXZZKAWDSP-UHFFFAOYSA-N
| pregnancy_category = 
| legal_AU =      <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK =      <!-- GSL        / P      / POM / CD -->
| legal_US =      <!-- OTC                  / Rx-only  -->
| legal_status =  
| routes_of_administration =  
}}
}}
__NOTOC__
{{SI}}
{{CMG}}
{{CMG}}


==Overview==
'''Indoramin''' (trade names '''Baratol''' and '''Doralese''') is a [[piperidine]] [[antiadrenergic]] agent.


It is an [[alpha-1 receptor|alpha-1]] selective adrenoceptor antagonist<ref name="pmid3955309">{{cite journal |author=Pierce V, Shepperson NB, Todd MH, Waterfall JF |title=Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin |journal=Br. J. Pharmacol. |volume=87 |issue=2 |pages=433–441 |date=February 1986 |pmid=3955309 |pmc=1916533 |doi= 10.1111/j.1476-5381.1986.tb10834.x|url=}}</ref> with direct myocardial depression action; therefore, it results in no reflex [[tachycardia]]. It is also used in [[benign prostatic hyperplasia]] (BPH).<ref>{{cite web|url=http://www.medicines.org.uk/Guides/indoramin%20hydrochloride/prostatic%20hyperplasia%20(benign)|title=Indoramin 20mg tablets|publisher=''Medicines.org.uk''|date= April 20, 2011|accessdate=September 30, 2012}}</ref>


'''Indoramin''' (trade name '''Baratol''') is a [[piperidine]] [[antiadrenergic]] agent. its an [[alpha-1 receptor|alpha-1]] selective adrenoceptor antagonist.
It is commonly synthesized from [[tryptophol]].<ref>Ullman's encyclopedia of Industrial Chemistry, Sixth Edition, 2002.</ref>
Indoramin is a α-adrenoceptor antagonist which acts selectively and competitively on post-synaptic α1-adrenoceptors, causing a decrease in peripheral vascular resistance, relaxation of the bladder neck and contraction of the detrusor.1–3 In palliative care, indoramin is used for hesitancy of micturition associated with benign prostatic hypertrophy.4,5 Other selective α1-antagonists are available, namely prazosin, tamsulosin and terazosin.6 All may cause severe hypotension, particularly with the first dose and in patients receiving diuretics or other antihypertensive medication.7 Low cost is the only advantage in using prazosin; this has to be balanced against ease of compliance with tamsulosin and terazosin (o.d. compared to b.d.). Indoramin is probably the safest in debilitated patients.6 Muscarinic drugs and anticholinesterases are sometimes preferable to an α-adrenoceptor antagonist, e.g. bethanechol 10–25mg t.d.s., distigmine 5mg o.d. If necessary, one of these may be used concurrently with indoramin. Indoramin is also licensed for use in the management of hypertension


==Dosage==
Indoramin is commonly prescribed as 20mg tablets when used in BPH.<ref>{{cite web|url=http://www.nhs.uk/medicine-guides/pages/MedicineOverview.aspx?condition=Prostatic%20hyperplasia%20(benign)&medicine=indoramin%20hydrochloride|title=Indoramin hydrochloride|publisher=''National Health Service (UK)''|accessdate=September 30, 2012}}</ref>
==Side Effects==
Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain, [[hypotension]], [[postural hypotension]], depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, and [[palpitations]].<ref>{{cite web|url=http://www.medicines.org.uk/Guides/indoramin%20hydrochloride/prostatic%20hyperplasia%20(benign)|title=Indoramin 20mg tablets|publisher=''Medicines.org.uk''|accessdate=September 30, 2012}}</ref>
==References==
{{reflist|2}}


{{Antihypertensives and diuretics}}
{{Antihypertensives and diuretics}}


[[Category:Alpha blockers]]
[[Category:Alpha blockers]]
[[Category:Drugs]]
[[Category:Antihypertensive agents]]
{{WikiDoc Help Menu}}
[[Category:Cardiovascular Drugs]]
{{WikiDoc Sources}}
[[Category:Drug]]
 
[[hu:Indoramin]]

Latest revision as of 23:22, 24 July 2014

{{Drugbox | Verifiedfields = changed | verifiedrevid = 461936008 | IUPAC_name = N-{1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl}benzamide | image = Indoramin_svg.png

| tradename = | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_UK = | legal_US = | legal_status = | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ☒N | CAS_number = 26844-12-2 | ATC_prefix = C02 | ATC_suffix = CA02 | PubChem = 33625 | IUPHAR_ligand = 501 | DrugBank_Ref =  ☑Y | DrugBank = | ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 31014 | UNII_Ref =  ☑Y | UNII = 0Z802HMY7H | KEGG_Ref =  ☑Y | KEGG = D04531 | ChEMBL_Ref =  ☑Y | ChEMBL = 279516

| C=22 | H=25 | N=3 | O=1 | molecular_weight = 347.454 g/mol | smiles = O=C(c1ccccc1)NC4CCN(CCc3c2ccccc2nc3)CC4 | InChI = 1/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26) | InChIKey = JXZZEXZZKAWDSP-UHFFFAOYAC | StdInChI_Ref =  ☑Y | StdInChI = 1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26) | StdInChIKey_Ref =  ☑Y | StdInChIKey = JXZZEXZZKAWDSP-UHFFFAOYSA-N }}

WikiDoc Resources for Indoramin

Articles

Most recent articles on Indoramin

Most cited articles on Indoramin

Review articles on Indoramin

Articles on Indoramin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Indoramin

Images of Indoramin

Photos of Indoramin

Podcasts & MP3s on Indoramin

Videos on Indoramin

Evidence Based Medicine

Cochrane Collaboration on Indoramin

Bandolier on Indoramin

TRIP on Indoramin

Clinical Trials

Ongoing Trials on Indoramin at Clinical Trials.gov

Trial results on Indoramin

Clinical Trials on Indoramin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Indoramin

NICE Guidance on Indoramin

NHS PRODIGY Guidance

FDA on Indoramin

CDC on Indoramin

Books

Books on Indoramin

News

Indoramin in the news

Be alerted to news on Indoramin

News trends on Indoramin

Commentary

Blogs on Indoramin

Definitions

Definitions of Indoramin

Patient Resources / Community

Patient resources on Indoramin

Discussion groups on Indoramin

Patient Handouts on Indoramin

Directions to Hospitals Treating Indoramin

Risk calculators and risk factors for Indoramin

Healthcare Provider Resources

Symptoms of Indoramin

Causes & Risk Factors for Indoramin

Diagnostic studies for Indoramin

Treatment of Indoramin

Continuing Medical Education (CME)

CME Programs on Indoramin

International

Indoramin en Espanol

Indoramin en Francais

Business

Indoramin in the Marketplace

Patents on Indoramin

Experimental / Informatics

List of terms related to Indoramin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Indoramin (trade names Baratol and Doralese) is a piperidine antiadrenergic agent.

It is an alpha-1 selective adrenoceptor antagonist[1] with direct myocardial depression action; therefore, it results in no reflex tachycardia. It is also used in benign prostatic hyperplasia (BPH).[2]

It is commonly synthesized from tryptophol.[3]

Dosage

Indoramin is commonly prescribed as 20mg tablets when used in BPH.[4]

Side Effects

Drowsiness, dizziness, dry mouth, nasal congestion, headache, fatigue, weight gain, hypotension, postural hypotension, depression, problems with ejaculation, diarrhoea, nausea, increased need to pass urine, and palpitations.[5]

References

  1. Pierce V, Shepperson NB, Todd MH, Waterfall JF (February 1986). "Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin". Br. J. Pharmacol. 87 (2): 433–441. doi:10.1111/j.1476-5381.1986.tb10834.x. PMC 1916533. PMID 3955309.
  2. "Indoramin 20mg tablets". Medicines.org.uk. April 20, 2011. Retrieved September 30, 2012.
  3. Ullman's encyclopedia of Industrial Chemistry, Sixth Edition, 2002.
  4. "Indoramin hydrochloride". National Health Service (UK). Retrieved September 30, 2012.
  5. "Indoramin 20mg tablets". Medicines.org.uk. Retrieved September 30, 2012.